Top News in R&D





 Global Health Technologies Coalition 


R&D News Roundup: January 29, 2024


Top News in R&D

COVID and beyond: Labs unite to boost genomic surveillance globally
Reuters (1/25)

The Genomic Surveillance Unit at the Wellcome Sanger Institute and the Centre for Epidemic Response and Innovation at Stellenbosch University are partnering to advance the practice of genomic surveillance, which has been around for decades but really came to the forefront during the COVID-19 pandemic and has the potential to improve global efforts against other infectious diseases, including malaria and cholera. During the COVID-19 pandemic, there was huge global investment in genomic surveillance infrastructure, with the Stellenbosch lab being the first to confirm the discovery of the Beta and Omicron variants. In the last year alone, the work of the two labs has contributed to doubling the number of sequences available for dengue, chikungunya, and malaria parasites. Genomic surveillance uses sequencing to get data about the genetic material of a pathogen, which is then used to track how the pathogen is changing or spreading.

Japanese researchers develop one-minute bioluminescent COVID-19 test
360Dx (1/24)

Researchers from the Health and Medical Research Institute at Japan’s National Institute of Advanced Industrial Science and Technology have developed a bioluminescent assay that could serve as a rapid, low-cost, and convenient test to complement laboratory testing for COVID-19. The test uses a bioluminescent molecule found in some small crustaceans that glows when it reacts with the virus that causes COVID-19 in a saliva sample and can be used with commercially available handheld luminometers at the point-of-care. The research team is planning for initial commercialization in the Japanese and US markets.

Gates Foundation awards ProteinLogic, Stellenbosch University $1.35M for TB treatment monitoring
360Dx (1/22), features the Gates Foundation

ProteinLogic and Stellenbosch University will use a $1.35 million grant from the Bill & Melinda Gates Foundation to determine whether an immunoassay technology being developed by ProteinLogic can be used to monitor treatment response to tuberculosis (TB) antimicrobial chemotherapy in patients. ProteinLogic's ImmiPrint testing technology is a protein-based test based on predictive models developed through machine learning that aims to offer rapid, efficient, and cost-effective discovery of diagnostic biomarkers across multiple diseases. Its new partner, Stellenbosch University, has been leading clinical trials on TB diagnostic biomarkers. In the face of the growing threat of drug-resistant strains of Mycobacterium tuberculosis, there is an urgent need for new technologies to monitor the effectiveness of current treatments, in addition to the need for novel treatments and prevention methods for TB.



News from GHTC

GHTC contributes to statements delivered at WHO Executive Board meeting on NTDs, TB, and AMR
GHTC news announcement (1/26)

Promising new ‘circRNA’ vaccines explored in CEPI-HMRI collaboration
Coalition for Epidemic Preparedness Innovations (CEPI) press release (1/25)

Opinion: Why drug resistance is becoming one of our biggest global health security blind-spots
World Economic Forum article (1/24), written by the Global Antibiotic Research & Development Partnership 

Global pandemic preparedness report reveals lack of investment in therapeutics and vaccines
Health Policy Watch (1/24), features Policy Cures Research, CEPI, FIND, Medicines Patent Pool, and the Drugs for Neglected Diseases initiative

Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines
CEPI press release (1/23)



Highlights From the Week



COVID-19 R&D Roundup



Upcoming Events

January 31
Neglected Disease G-FINDER Report launch

January 31
World NTD Day event
Paris, France

January 31
Webinar on global health innovation across sectors

February 6-7
Antimicrobial Chemotherapy Conference

February 14
Webinar on improving antibiotic access

February 26
Forum on Gender, Health & Science
Shah Alam, Malaysia; Virtual

February 27
Webinar on antibiotic R&D pull incentives